-
Founded in:
1995-05-04 -
Country:
China -
Address:
No. 8 Yangzi Road, Shijiazhuang Economic and Technological Development Zone -
Tax NO.:
91130182601702614Y -
Registered Funds:
237.4751 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cyclosporin A |
|
59865-13-3 | 20 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Amphotericin B |
No specific description provided
More
No specific description provided |
1397-89-3 | 12 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clindamycin phosphate |
A chemical semi-synthetic clindamycin derivative with no antibacterial activity in vitro. It is rapidly hydrolyzed into clindamycin to exert its pharmacological activity after entering the body. Its antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin. It can be administered orally, intramuscularly and intravenously. Its antibacterial effect is 4-8 times stronger than that of lincomycin, with good absorption and high bone concentration, and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, and Necrococcus).
More
A chemical semi-synthetic clindamycin derivative with no antibacterial activity in vitro. It is rapidly hydrolyzed into clindamycin to exert its pharmacological activity after entering the body. Its antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin. It can be administered orally, intramuscularly and intravenously. Its antibacterial effect is 4-8 times stronger than that of lincomycin, with good absorption and high bone concentration, and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, and Necrococcus). |
24729-96-2 | 33 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Capastat sulfate |
Unspecified
More
Unspecified |
1405-37-4 | 3 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Rapamycin |
No specific description provided
More
No specific description provided |
53123-88-9 | 22 |